Donate
Join Us

FDA

Ben Deverman, PhD | Senior Director of Vector Engineering at the Broad Institute of MIT and Harvard
April 18, 2025
How Will Cuts to FDA and NIH Impact Gene Therapy Clinical Trials and Rett Syndrome Research?
FDA Selects Neurogene Rett Program for START Pilot Program
June 3, 2024
FDA Selects Neurogene Rett Program for START Pilot Program
daybue-key-facts-banner
March 23, 2023
DAYBUE (trofinetide): Key Facts for Parents
hero-many-ways-to-participate-in-fda
March 4, 2022
Many ways to participate in the public meeting with the FDA on March 11
hero-outcomes-of-a-marathon-fda-meeting-on-the-safety-of-gene-replacement
September 28, 2021
Outcomes of a Marathon FDA Meeting on the Safety of Gene Replacement
hero-taysha-gene-therapies-shares-letter-to-the-rett-syndrome-community
September 24, 2021
Taysha Gene Therapies Shares Letter to the Rett Syndrome Community
hero-the-future-is-now
August 7, 2018
The Future is Now
hero-road-to-fda-approval
February 7, 2018
The Road to FDA Approval
hero-orphan-drug-meaning
March 30, 2017
Orphan Drug Designation: What Does it Mean?
hero-rare-disease-drug-approval-sparks-controversy
December 14, 2016
Rare Disease Drug Approval Sparks Controversy
hero-educating-the-fda-on-breathing-problems
March 31, 2016
Educating the FDA on Breathing Problems
hero-rsrt-awards-530000-to-neurolixis-for-clinical-development-of-nlx-101
June 24, 2015
RSRT Awards $530,000 to Neurolixis for Clinical Development of NLX-101
thumbnail-blog
March 1, 2015
Interview with Former Director of the FDA Office of Orphan Product Development, Timothy Coté
hero-transparency-clinical-trials
May 20, 2014
Transparency in Clinical Trials
$40M
Take Action